ArticleNeuroradiology2026
Reduced choroid plexus volume aggravates the glymphatic system burden in patients with patent foramen ovale-related migraine with aura.
Article in Neuroradiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe choroid plexus (ChP) produces cerebrospinal fluid (CSF) and serves as a crucial component of the glymphatic system. This study investigated the characteristics of choroid plexus volume (CPV) changes in patients with patent foramen ovale-related migraine with aura (PFO-M), analyzed its correlation with migraine severity (including both visual analogue scale [VAS] and monthly migraine frequency [MMF]), and elucidated the mechanism of chronic long-term injury on ChP as well as the therapeutic significance of PFO closure.
methodsA prospective study was conducted to enroll 76 patients with PFO-related migraine with aura (PFO group) and 50 healthy controls (HC group) who were treated in our hospital from September 2023 to September 2025. 3.0T magnetic resonance imaging (MRI) was used to measure the lateral ventricular CPV of all subjects, and both VAS and MMF were adopted to evaluate the migraine severity of patients. Intergroup differences in CPV were calculated, and the correlations between CPV and migraine severity indicators (VAS and MMF) in the PFO-M group was analyzed. 26 patients underwent follow-up MRI at 6 months postoperatively to measure CPV and reassess the VAS and MMF, and pre- and post-closure changes in these metrics were compared.
results(1) The CPV in the PFO-M group was significantly smaller than that in the HC group (1709.76 ± 468.23 mm³ vs. 2443.68 ± 797.48 mm³, t=-5.875, P < 0.001). (2) A significant negative correlation was observed between CPV and VAS (r=-0.788, P < 0.001) and MMF (r=-0.769, P < 0.001) in the PFO-M group. (3) Migraine severity in the PFO-M group at 6 months postoperatively was significantly lower compared with pre-closure levels (VAS: 1.04 ± 1.54 vs. 6.12 ± 1.84, t = 10.718, P < 0.001; MMF: 0.92 ± 1.32 vs. 5.08 ± 1.76, t = 10.316, P < 0.001). (4) There was no statistically significant difference in CPV of the PFO-M group between pre- and 6 months post-closure (1658.23 ± 421.99 mm³ vs. 1666.54 ± 486.86 mm³, t = 0.225, P = 0.823).
conclusionPatients with PFO-related migraine with aura show reduced choroid plexus volume correlated with migraine severity. PFO closure improves migraine symptoms, without significant changes in choroid plexus volume at 6 months, suggesting longer follow-up is needed.
Indexed as
Identifiers
42371032What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.